# US 2023/0069441 A1 · Use of rhodococcus ruber cell wall skeleton in regenerative medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069441 A1
- Document ID: US20230069441A1
- Status: Published application
- Kind: A1
- Application number: 17/792,396
- Filed: 2021-01-20
- Published: 2023-03-02
- Earliest claimed: 2020-01-21
- Assignees: Liaoning Greatest Bio-Pharmaceutical Co., Ltd.
- Applicants: Liaoning Greatest Bio-Pharmaceutical Co., Ltd.
- Inventors: Bo Gai; Chunyan Dou; Peisheng Jin; Yi Zhang; Guoying Zhang
- Web page: https://patentgrep.com/patent/US20230069441A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C12N 1/205: Bacterial isolates
- C12N 2500/34: Sugars
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Provided is a use of Rhodococcus ruber cell wall skeleton in promoting the proliferation of stem cells, promoting the growth of stem cells, promoting the differentiation of stem cells, promoting the migration of stem cells, and improving the survival rate of stem cells; the stem cells are selected from: adult stem cells, iPSCs, and mesenchymal stem cells.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method of regulating stem cells comprising exposing the stem cells to a product derived from Rhodococcus ruber cell wall; wherein the ratio of the number of stem cells to the product derived from Rhodococcus ruber cell wall is 1 to 100 stem cells per 1 ng of the product derived from Rhodococcus ruber cell wall.

### Claim 15 (depends on 14)

The method of claim 14, wherein the ratio is 5 to 50 stem cells per 1 ng of the product derived from Rhodococcus ruber cell wall; and the regulation is selected from one of the following: promoting the proliferation of stem cells, promoting the growth of stem cells, promoting the differentiation of stem cells, promoting the migration of stem cells, improving the survival rate of stem cells, and a combination thereof.

### Claim 16 (depends on 14)

The method of claim 14, wherein the stem cells are selected from the group consisting of: adult stem cells, iPSCs mesenchymal stem cells, and combinations thereof; and the product derived from Rhodococcus ruber cell wall is Rhodococcus ruber cell wall or a component thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the stem cells are mesenchymal stem cells selected from the group consisting of: bone marrow mesenchymal stem cells, adipose-derived mesenchymal stem cells, synovial mesenchymal stem cells, umbilical cord mesenchymal stem cells, umbilical cord blood mesenchymal stem cells, placental mesenchymal stem cells, amniotic mesenchymal stem cells, liver mesenchymal stem cells, muscle mesenchymal stem cells, lung mesenchymal stem cells, pancreatic mesenchymal stem cells, and dental pulp mesenchymal stem cells.

### Claim 18 (depends on 16)

The method of claim 16, wherein the mesenchymal stem cells are adipose-derived mesenchymal stem cells; and the adult stem cells are epithelial adult stem cells.

### Claim 19 (depends on 14)

The method according to claim 14, wherein the product derived from Rhodococcus ruber cell wall is obtained by the following method comprising the following steps:
1) providing a Rhodococcus ruber;
2) disrupting the Rhodococcus ruber to obtain a disrupted product;
3.1) optionally, removing lipids from the disrupted product;
3.2) optionally, removing nucleic acids from the disrupted product;
3.3) optionally, removing proteins from the disrupted product;
3.4) obtaining a product derived from Rhodococcus ruber cell wall;
4) optionally, removing water from the product derived from Rhodococcus ruber cell wall, preferably lyophilizing the product derived from Rhodococcus ruber cell wall;
5) optionally, aliquoting;
wherein, steps 3.1), 3.2) and 3.3) are interchangeable in order or performed in parallel; step 4) and step 5) are interchangeable in order.

### Claim 20 (depends on 14)

The method of claim 14, wherein the Rhodococcus ruber is CGMCC No. 17431 deposited on Mar. 22, 2019.

### Claim 21

A cell culture medium comprising a product derived from Rhodococcus ruber cell wall, wherein the product derived from Rhodococcus ruber cell wall is Rhodococcus ruber cell wall or a component thereof.

### Claim 22 (depends on 21)

The cell culture medium according to claim 21, wherein the product derived from Rhodococcus ruber cell wall is obtained by the following method comprising the following steps:
1) providing a Rhodococcus ruber;
2) disrupting the Rhodococcus ruber to obtain a disrupted product;
3.1) optionally, removing lipids from the disrupted product;
3.2) optionally, removing nucleic acids from the disrupted product;
3.3) optionally, removing proteins from the disrupted product;
3.4) obtaining a product derived from Rhodococcus ruber cell wall;
4) optionally, removing water from the product derived from Rhodococcus ruber cell wall, preferably lyophilizing the product derived from Rhodococcus ruber cell wall;
5) optionally, aliquoting;
wherein, steps 3.1), 3.2) and 3.3) are interchangeable in order or performed in parallel; step 4) and step 5) are interchangeable in order.

### Claim 23 (depends on 21)

The cell culture medium according to claim 21, wherein the Rhodococcus ruber is CGMCC No. 17431 deposited on Mar. 22, 2019.

### Claim 24

A method for promoting wound healing, comprising exposing a subject having a wound to a therapeutically effective amount of stem cells and a product derived from Rhodococcus ruber cell wall, wherein the stem cells are selected from the group consisting of adult stem cells, mesenchymal stem cells and iPSCs and the ratio of the number of stem cells to the product derived from Rhodococcus ruber cell wall is 1 to 100 stem cells per 1 ng of the product derived from Rhodococcus ruber cell wall.

### Claim 25 (depends on 24)

The method of claim 24, wherein the wound is a diabetes-related wound and the ratio is 5 to 50 stem cells per 1 ng of the product derived from Rhodococcus ruber cell wall; and the regulation is selected from one of the following: promoting the proliferation of stem cells, promoting the growth of stem cells, promoting the differentiation of stem cells, promoting the migration of stem cells, improving the survival rate of stem cells, and a combination thereof.

### Claim 26 (depends on 24)

The method of claim 24, wherein the stem cells are selected from the group consisting of: adult stem cells, iPSCs, mesenchymal stem cells and combinations thereof; and the Rhodococcus ruber is CGMCC No. 17431 deposited on Mar. 22, 2019.

### Claim 27 (depends on 26)

The method of claim 26, wherein the stem cells are mesenchymal stem cells selected from the group consisting of: bone marrow mesenchymal stem cells, adipose-derived mesenchymal stem cells, synovial mesenchymal stem cells, umbilical cord mesenchymal stem cells, umbilical cord blood mesenchymal stem cells, placental mesenchymal stem cells, amniotic mesenchymal stem cells, liver mesenchymal stem cells, muscle mesenchymal stem cells, lung mesenchymal stem cells, pancreatic mesenchymal stem cells and dental pulp mesenchymal stem cells.

### Claim 28 (depends on 24)

The method of claim 24, wherein the mesenchymal stem cells are adipose-derived mesenchymal stem cells.

### Claim 29 (depends on 24)

The method of claim 24, wherein stem cells are adult stem cells, and the adult stem cells are epithelial adult stem cells and the product derived from Rhodococcus ruber cell wall is Rhodococcus ruber cell wall or a component thereof.

### Claim 30

A pharmaceutical composition comprising:
(i) stem cells, and
(ii) a product derived from Rhodococcus ruber cell wall, wherein the stem cells are selected from the group consisting of adult stem cells, mesenchymal stem cells, iPSCs, or a combination thereof; and the ratio of the number of stem cells to the product derived from Rhodococcus ruber cell wall is: 1 to 100 stem cells to 1 ng of the product derived from Rhodococcus ruber cell wall.

### Claim 31 (depends on 14)

The pharmaceutical composition of claim 14, wherein the ratio is 5 to 50 stem cells per 1 ng of the product derived from Rhodococcus ruber cell wall; and the regulation is selected from one of the following: promoting the proliferation of stem cells, promoting the growth of stem cells, promoting the differentiation of stem cells, promoting the migration of stem cells, improving the survival rate of stem cells, and a combination thereof.

### Claim 32 (depends on 14)

The pharmaceutical composition of claim 14, wherein the stem cells are selected from the group consisting of: adult stem cells, iPSCs, mesenchymal stem cells, and combinations thereof.

### Claim 33 (depends on 16)

The pharmaceutical composition of claim 16, wherein the stem cells are mesenchymal stem cells selected from the group consisting of: bone marrow mesenchymal stem cells, adipose-derived mesenchymal stem cells, synovial mesenchymal stem cells, umbilical cord mesenchymal stem cells, umbilical cord blood mesenchymal stem cells, placental mesenchymal stem cells, amniotic mesenchymal stem cells, liver mesenchymal stem cells, muscle mesenchymal stem cells, lung mesenchymal stem cells, pancreatic mesenchymal stem cells and dental pulp mesenchymal stem cells; and the product derived from Rhodococcus ruber cell wall is Rhodococcus ruber cell wall or a component thereof from Rhodococcus ruber deposited in CGMCC under the number CGMCC No. 17431 on Mar. 22, 2019.
